Forest pays $240mm up front for exclusive US rights to Merck's Saphris
Spec pharma Forest Laboratories Inc. (CNS, cardiovascular, GI, respiratory, and infectious disease therapies) paid $240mm up front for exclusive US rights to Merck & Co. Inc.’s antipsychotic drug Saphris (asenapine). Forest could also pay undisclosed sales milestones.
- Specialty Pharmaceuticals
- Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com